Malaga Cove Capital LLC Buys New Position in Stryker Corporation $SYK

Malaga Cove Capital LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 584 shares of the medical technology company’s stock, valued at approximately $231,000.

A number of other large investors also recently modified their holdings of SYK. Brighton Jones LLC boosted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Brown Advisory Inc. raised its position in shares of Stryker by 2.2% during the first quarter. Brown Advisory Inc. now owns 47,079 shares of the medical technology company’s stock valued at $17,525,000 after buying an additional 993 shares during the last quarter. Axxcess Wealth Management LLC lifted its stake in shares of Stryker by 3.9% in the first quarter. Axxcess Wealth Management LLC now owns 5,223 shares of the medical technology company’s stock valued at $1,944,000 after buying an additional 196 shares during the period. Cerity Partners LLC grew its position in Stryker by 17.4% during the first quarter. Cerity Partners LLC now owns 271,069 shares of the medical technology company’s stock worth $100,912,000 after buying an additional 40,140 shares in the last quarter. Finally, Mar Vista Investment Partners LLC increased its stake in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after acquiring an additional 8,353 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE:SYK opened at $355.74 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business’s fifty day moving average price is $374.63 and its two-hundred day moving average price is $380.99. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The stock has a market capitalization of $136.04 billion, a price-to-earnings ratio of 47.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the company earned $2.87 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 520,500 shares of company stock worth $184,803,065. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on SYK. BTIG Research raised their price objective on Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research report on Monday. Truist Financial reiterated a “hold” rating and set a $392.00 price target (down previously from $407.00) on shares of Stryker in a research note on Monday, November 3rd. UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $433.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.